Vice President of Global Research and Development/Regulatory Affairs, Elanco Animal Health, Inc.
Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Previously, he held the role of Global Brand Development Leader-Pain in Eli Lilly and Company Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit.
Past roles included serving as Executive Director, Global External R&D, at Lilly, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was c-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, Md., cardiovascular drug discovery start-up.
Previously, Mr. Schacht held roles as Managing Director of Lilly University, Director of Knowledge Management, and Manager of Strategy and Productivity for Discovery Research.
Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent five years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. He studied Organic Chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.